ArticleCurrent genetics2007
Cytoplasmic Clb2 is required for timely inactivation of the mitotic inhibitor Swe1 and normal bud morphogenesis in Saccharomyces cerevisiae.
Article in Current genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- The cell cycle, autophagy, and cell wall integrity pathway jointly governed by MoSwe1 in Magnaporthe oryzae.Cell communication and signaling : CCS · 2024Article
- Post-translational modification directs nuclear and hyphal tip localization of Candida albicans mRNA-binding protein Slr1.Molecular microbiology · 2017Article
- Spatially distinct functions of Clb2 in the DNA damage response.Cell cycle (Georgetown, Tex.) · 2014Article
- Control analysis of the eukaryotic cell cycle using gene copy-number series in yeast tetraploids.BMC genomics · 2013Article
- The role of autophagy in genome stability through suppression of abnormal mitosis under starvation.PLoS genetics · 2013Article
- Ergodic sets as cell phenotype of budding yeast cell cycle.PloS one · 2012Article
- Cdk1 and SUMO regulate Swe1 stability.PloS one · 2010Article
- Nucleocytoplasmic trafficking of G2/M regulators in yeast.Molecular biology of the cell · 2008Article
- Optimization of yeast cell cycle analysis and morphological characterization by multispectral imaging flow cytometry.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcellular localization is an important determinant of substrate and functional specificity for cyclin-cyclin dependent kinase (CDK) complexes. This work addresses the cytoplasmic function of the budding yeast mitotic cyclin Clb2, which is mostly nuclear but is also present in the bulk cytoplasm and at the mother-bud neck. Clb2 contains two leucine-rich nuclear export signals (NESs)--one of which we newly describe here--that maintain its presence in the cytoplasm. Yeast strains bearing mutations in one or both of these NESs have elongated buds, indicative of a G2/M cell cycle delay. A small number of these cells exhibit a filamentous-like morphology under conditions that do not normally induce filamentous growth. These phenotypes are enhanced by deletion of the other three mitotic cyclins (CLB1,3,4) and are dependent on expression of Swe1, the yeast Cdk1 inhibitory kinase. Deltaclb1,3,4 Deltabud3 cells, which fail to localize Clb2 to the bud neck, also exhibit a Swe1-dependent elongated bud phenotype. Our results support a model in which cytoplasmic Clb2-Cdk1 is required for timely inactivation of Swe1 at the G2/M transition and bud neck targeting of Clb2 contributes to the efficiency of this process. Cytoplasmic Clb2 may also be important for repression of filamentous growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.